Home Journal Club	FAQ My Amedeo About Tranquillis Services	Flying Publisher
	Books, Journals, Podcasts, Weekly Updates, by Amedeo

Malaria

Free Subscription Articles published in Vaccine Retrieve available abstracts of 56 articles: HTML format Text format

Single Articles

February 2010
1. JONGWUTIWES S , Putaporntip C, Hughes AL
   Bottleneck effects on vaccine-candidate antigen diversity of malaria parasites in Thailand.
   Vaccine. 2010.
   PubMed     Text format     Related articles    Abstract available
   
   
   
2. LIMA JC JR , Banic DM, Tran TM, Meyer VS, et al
   Promiscuous T-cell epitopes of Plasmodium merozoite surface protein 9 (PvMSP9) induces IFN-gamma and IL-4 responses in individuals naturally exposed to malaria in the Brazilian Amazon.
   Vaccine. 2010.
   PubMed     Text format     Related articles    Abstract available
   
   
   
3. BRUDER JT , Stefaniak ME, Patterson NB, Chen P, et al
   Adenovectors induce functional antibodies capable of potent inhibition of blood stage malaria parasite growth.
   Vaccine. 2010.
   PubMed     Text format     Related articles    Abstract available
   
   
   January 2010
4. SINGH B , Cabrera-Mora M, Jiang J, Galinski M, et al
   Genetic linkage of autologous T cell epitopes in a chimeric recombinant construct improves anti-parasite and anti-disease protective effect of a malaria vaccine candidate.
   Vaccine. 2010.
   PubMed     Text format     Related articles    Abstract available
   
   
   
5. PINZON CG , Curtidor H, Garcia J, Vanegas M, et al
   Sequences of the Plasmodium falciparum cytoadherence-linked asexual protein 9 implicated in malaria parasite invasion to erythrocytes.
   Vaccine. 2010.
   PubMed     Text format     Related articles    Abstract available
   
   
   
6. PIERCE MA , Ellis RD, Martin LB, Malkin E, et al
   Phase 1 safety and immunogenicity trial of the Plasmodium falciparum blood-stage malaria vaccine AMA1-C1/ISA 720 in Australian adults.
   Vaccine. 2010.
   PubMed     Text format     Related articles    Abstract available
   
   
   December 2009
7. VEKEMANS J , Leach A, Cohen J
   Development of the RTS,S/AS malaria candidate vaccine.
   Vaccine. 2009;27S6:G67-G71.
   PubMed     Text format     Related articles    Abstract available
   
   
   
8. GIHA HA , Nasr A, Iriemenam NC, Balogun HA, et al
   Age-dependent association between IgG2 and IgG3 subclasses to Pf332-C231 antigen and protection from malaria, and induction of protective antibodies by sub-patent malaria infections, in Daraweesh.
   Vaccine. 2009.
   PubMed     Text format     Related articles    Abstract available
   
   
   
9. BALOGUN HA , Vasconcelos NM, Lindberg R, Haeggstrom M, et al
   Immunogenicity and antigenic properties of Pf332-C231, a fragment of a non-repeat region of the Plasmodium falciparum antigen Pf332.
   Vaccine. 2009;28:90-7.
   PubMed     Text format     Related articles    Abstract available
   
   
   
10. TRAORE B , Kone Y, Doumbo S, Doumtabe D, et al
    The TLR9 agonist CpG fails to enhance the acquisition of Plasmodium falciparum-specific memory B cells in semi-immune adults in Mali.
    Vaccine. 2009;27:7299-303.
    PubMed     Text format     Related articles    Abstract available
    
    
    November 2009
11. BRAGA CJ , Massis LM, Sbrogio-Almeida ME, Alencar BC, et al
    CD8(+) T cell adjuvant effects of Salmonella FliCd flagellin in live vaccine vectors or as purified protein.
    Vaccine. 2009.
    PubMed     Text format     Related articles    Abstract available
    
    
    October 2009
12. SAGARA I , Ellis RD, Dicko A, Niambele MB, et al
    A randomized and controlled Phase 1 study of the safety and immunogenicity of the AMA1-C1/Alhydrogel((R))+CPG 7909 vaccine for Plasmodium falciparum malaria in semi-immune Malian adults.
    Vaccine. 2009.
    PubMed     Text format     Related articles    Abstract available
    
    
    
13. SCHMIDT NW , Butler NS, Harty JT
    CD8 T cell immunity to Plasmodium permits generation of protective antibodies after repeated sporozoite challenge.
    Vaccine. 2009;27:6103-6.
    PubMed     Text format     Related articles    Abstract available
    
    
    
14. BERTHOUD TK , Fletcher H, Porter D, Thompson F, et al
    Comparing human T cell and NK cell responses in viral-based malaria vaccine trials.
    Vaccine. 2009.
    PubMed     Text format     Related articles    Abstract available
    
    
    September 2009
15. GIRALDO MA , Arevalo-Pinzon G, Rojas-Caraballo J, Mongui A, et al
    Vaccination with recombinant Plasmodium vivax MSP-10 formulated in different adjuvants induces strong immunogenicity but no protection.
    Vaccine. 2009.
    PubMed     Text format     Related articles    Abstract available
    
    
    
16. BROWN GV , Moorthy VS, Reed Z, Mendis K, et al
    Priorities in research and development of vaccines against Plasmodium vivax malaria.
    Vaccine. 2009.
    PubMed     Text format     Related articles    Abstract available
    
    
    
17. ESEN M , Kremsner PG, Schleucher R, Gassler M, et al
    Safety and immunogenicity of GMZ2-A MSP3-GLURP fusion protein malaria vaccine candidate.
    Vaccine. 2009.
    PubMed     Text format     Related articles    Abstract available
    
    
    August 2009
18. RODRIGUEZ A , Mintardjo R, Tax D, Gillissen G, et al
    Evaluation of a prime-boost vaccine schedule with distinct adenovirus vectors against malaria in rhesus monkeys.
    Vaccine. 2009.
    PubMed     Text format     Related articles    Abstract available
    
    
    
19. MOORTHY VS , Diggs C, Ferro S, Good MF, et al
    Report of a Consultation on the Optimization of Clinical Challenge Trials for Evaluation of Candidate Blood Stage Malaria Vaccines, 18-19 March 2009, Bethesda, MD, USA.
    Vaccine. 2009.
    PubMed     Text format     Related articles    Abstract available
    
    
    July 2009
20. BUENO LL , Morais CG, da Silva Soares I, Bouillet LE, et al
    Plasmodium vivax recombinant vaccine candidate AMA-1 plays an important role in adaptive immune response eliciting differentiation of dendritic cells.
    Vaccine. 2009.
    PubMed     Text format     Related articles    Abstract available
    
    
    
21. MUELLER I , Moorthy VS, Brown GV, Smith PG, et al
    Guidance on the evaluation of Plasmodium vivax vaccines in populations exposed to natural infection.
    Vaccine. 2009.
    PubMed     Text format     Related articles    Abstract available
    
    
    
22. BLAGBOROUGH AM , Sinden RE
    Plasmodium berghei HAP2 induces strong malaria transmission-blocking immunity in vivo and in vitro.
    Vaccine. 2009.
    PubMed     Text format     Related articles    Abstract available
    
    
    
23. HUAMAN MC , Mullen GE, Long CA, Mahanty S, et al
    Plasmodium falciparum apical membrane antigen 1 vaccine elicits multifunctional CD4 cytokine-producing and memory T cells.
    Vaccine. 2009.
    PubMed     Text format     Related articles    Abstract available
    
    
    
24. BERGMANN-LEITNER ES , Leitner WW, Duncan E, Savranskaya T, et al
    Molecular adjuvants for malaria DNA vaccines based on the modulation of host-cell apoptosis.
    Vaccine. 2009.
    PubMed     Text format     Related articles    Abstract available
    
    
    June 2009
25. MOORTHY SA , Yasawardena SG, Ramasamy R
    Age-dependent systemic antibody responses and immunisation-associated changes in mice orally and nasally immunised with Lactococcus lactis expressing a malaria parasite protein.
    Vaccine. 2009.
    PubMed     Text format     Related articles    Abstract available
    
    
    May 2009
26. BEJON P , Abdulla S, Lusingu J, Olotu A, et al
    Response to "Poor control vaccines in two randomised trials of malaria vaccine?"
    Vaccine. 2009.
    PubMed     Text format     Related articles   
    
    
    
27. SAGARA I , Dicko A, Ellis RD, Fay MP, et al
    A randomized controlled phase 2 trial of the blood stage AMA1-C1/Alhydrogel malaria vaccine in children in Mali.
    Vaccine. 2009;27:3090-8.
    PubMed     Text format     Related articles    Abstract available
    
    
    
28. FLUECK C , Frank G, Smith T, Jafarshad A, et al
    Evaluation of two long synthetic merozoite surface protein 2 peptides as malaria vaccine candidates.
    Vaccine. 2009;27:2653-61.
    PubMed     Text format     Related articles    Abstract available
    
    
    April 2009
29. ELLIS RD , Mullen GE, Pierce M, Martin LB, et al
    A Phase 1 study of the blood-stage malaria vaccine candidate AMA1-C1/Alhydrogel((R)) with CPG 7909, using two different formulations and dosing intervals.
    Vaccine. 2009.
    PubMed     Text format     Related articles    Abstract available
    
    
    March 2009
30. LYKE KE , Daou M, Diarra I, Kone A, et al
    Cell-mediated immunity elicited by the blood stage malaria vaccine apical membrane antigen 1 in Malian adults: Results of a Phase I randomized trial.
    Vaccine. 2009;27:2171-6.
    PubMed     Text format     Related articles    Abstract available
    
    
    
31. AABY P , Ravn H, Benn CS
    Poor control vaccines in two randomised trials of malaria vaccine?
    Vaccine. 2009.
    PubMed     Text format     Related articles   
    
    
    January 2009
32. BELL BA , Wood JF, Bansal R, Ragab H, et al
    Process development for the production of an E. coli produced clinical grade recombinant malaria vaccine for Plasmodium vivax.
    Vaccine. 2009.
    PubMed     Text format     Related articles    Abstract available
    
    
    
33. BONGFEN SE , Ntsama PM, Offner S, Smith T, et al
    The N-terminal domain of Plasmodium falciparum circumsporozoite protein represents a target of protective immunity.
    Vaccine. 2009;27:328-35.
    PubMed     Text format     Related articles    Abstract available
    
    
    December 2008
34. ROMERO JF , Ciabattini A, Guillaume P, Frank G, et al
    Intranasal administration of the synthetic polypeptide from the C-terminus of the circumsporozoite protein of Plasmodium berghei with the modified heat-labile toxin of Escherichia coli (LTK63) induces a complete protection against malaria challenge.
    Vaccine. 2008.
    PubMed     Text format     Related articles    Abstract available
    
    
    
35. CHATTOPADHYAY R , Conteh S, Li M, James ER, et al
    The Effects of radiation on the safety and protective efficacy of an attenuated Plasmodium yoelii sporozoite malaria vaccine.
    Vaccine. 2008.
    PubMed     Text format     Related articles    Abstract available
    
    
    
36. MOORTHY VS , Reed Z, Smith PG
    MALVAC 2008: Measures of efficacy of malaria vaccines in phase 2b and phase 3 trials-Scientific, regulatory and public health perspectives.
    Vaccine. 2008.
    PubMed     Text format     Related articles    Abstract available
    
    
    November 2008
37. REED ZH , Kieny MP, Engers H, Friede M, et al
    Comparison of immunogenicity of five MSP1-based malaria vaccine candidate antigens in rabbits.
    Vaccine. 2008.
    PubMed     Text format     Related articles    Abstract available
    
    
    October 2008
38. IRIEMENAM NC , Khirelsied AH, Nasr A, Elghazali G, et al
    Antibody responses to a panel of Plasmodium falciparum malaria blood-stage antigens in relation to clinical disease outcome in Sudan.
    Vaccine. 2008.
    PubMed     Text format     Related articles    Abstract available
    
    
    
39. YANDAR N , Pastorin G, Prato M, Bianco A, et al
    Immunological profile of a Plasmodium vivax AMA-1 N-terminus peptide-carbon nanotube conjugate in an infected Plasmodium berghei mouse model.
    Vaccine. 2008;26:5864-73.
    PubMed     Text format     Related articles    Abstract available
    
    
    
40. VANDERBERG JP
    Reflections on early malaria vaccine studies, the first successful human malaria vaccination, and beyond.
    Vaccine. 2008.
    PubMed     Text format     Related articles    Abstract available
    
    
    
41. MALKIN E , Hu J, Li Z, Chen Z, et al
    A Phase 1 trial of PfCP2.9: An AMA1/MSP1 chimeric recombinant protein vaccine for Plasmodium falciparum malaria.
    Vaccine. 2008.
    PubMed     Text format     Related articles    Abstract available
    
    
    
42. BERMUDEZ A , Vanegas M, Patarroyo ME
    Structural and immunological analysis of circumsporozoite protein peptides: A further step in the identification of potential components of a minimal subunit-based, chemically synthesised antimalarial vaccine.
    Vaccine. 2008.
    PubMed     Text format     Related articles    Abstract available
    
    
    September 2008
43. BARCLAY VC , Chan BH, Anders RF, Read AF, et al
    Mixed allele malaria vaccines: Host protection and within-host selection.
    Vaccine. 2008.
    PubMed     Text format     Related articles    Abstract available
    
    
    
44. BARGIERI DY , Rosa DS, Braga CJ, Carvalho BO, et al
    New malaria vaccine candidates based on the Plasmodium vivax Merozoite Surface Protein-1 and the TLR-5 agonist Salmonella Typhimurium FliC flagellin.
    Vaccine. 2008.
    PubMed     Text format     Related articles    Abstract available
    
    
    
45. TARTZ S , Russmann H, Kamanova J, Sebo P, et al
    Complete protection against P. berghei malaria upon heterologous prime/boost immunization against circumsporozoite protein employing Salmonella type III secretion system and Bordetella adenylate cyclase toxoid.
    Vaccine. 2008.
    PubMed     Text format     Related articles    Abstract available
    
    
    
46. PURCELL LA , Wong KA, Yanow SK, Lee M, et al
    Chemically attenuated Plasmodium sporozoites induce specific immune responses, sterile immunity and cross-protection against heterologous challenge.
    Vaccine. 2008;26:4880-4.
    PubMed     Text format     Related articles    Abstract available
    
    
    July 2008
47. MACKINNON MJ , Gandon S, Read AF
    Virulence evolution in response to vaccination: the case of malaria.
    Vaccine. 2008;26 Suppl 3:C42-52.
    PubMed     Text format     Related articles    Abstract available
    
    
    June 2008
48. LALITHA PV , Biswas S, Pillai CR, Saxena RK, et al
    Immunogenicity of a recombinant malaria vaccine candidate, domain I+II of AMA-1 ectodomain, from Indian P. falciparum alleles.
    Vaccine. 2008;.
    PubMed     Text format     Related articles    Abstract available
    
    
    
49. MORENO A , Caro-Aguilar I, Yazdani SS, Shakri AR, et al
    Preclinical assessment of the receptor-binding domain of Plasmodium vivax Duffy-binding protein as a vaccine candidate in rhesus macaques.
    Vaccine. 2008;.
    PubMed     Text format     Related articles    Abstract available
    
    
    
50. KATS LM , Wang L, Murhandarwati EE, Mitri K, et al
    Active immunisation with RAMA does not provide protective immunity against Plasmodium yoelii challenge despite its association with protective responses in endemic populations.
    Vaccine. 2008;26:3261-7.
    PubMed     Text format     Related articles    Abstract available
    
    
    April 2008
51. AGAK GW , Bejon P, Fegan G, Gicheru N, et al
    Longitudinal analyses of immune responses to Plasmodium falciparum derived peptides corresponding to novel blood stage antigens in coastal Kenya.
    Vaccine. 2008;26:1963-71.
    PubMed     Text format     Related articles    Abstract available
    
    
    March 2008
52. KESTER KE , Cummings JF, Ockenhouse CF, Nielsen R, et al
    Phase 2a trial of 0, 1, and 3 month and 0, 7, and 28 day immunization schedules of malaria vaccine RTS,S/AS02 in malaria-naive adults at the Walter Reed Army Institute of Research.
    Vaccine. 2008;.
    PubMed     Text format     Related articles    Abstract available
    
    
    
53. LOPERA-MESA TM , Kushwaha A, Mohmmed A, Chauhan VS, et al
    Plasmodium berghei merozoite surface protein-9: immunogenicity and protective efficacy using a homologous challenge model.
    Vaccine. 2008;26:1335-43.
    PubMed     Text format     Related articles    Abstract available
    
    
    January 2008
54. BUENO LL , Fujiwara RT, Soares IS, Braga EM, et al
    Direct effect of Plasmodium vivax recombinant vaccine candidates AMA-1 and MSP-1(19) on the innate immune response.
    Vaccine. 2008;.
    PubMed     Text format     Related articles    Abstract available
    
    
    November 2007
55. BERGMANN-LEITNER ES , Duncan EH, Leitner WW, Neutzner A, et al
    C3d-defined complement receptor-binding peptide p28 conjugated to circumsporozoite protein provides protection against Plasmodium berghei.
    Vaccine. 2007;25:7732-6.
    PubMed     Text format     Related articles    Abstract available
    
    
    October 2007
56. HUI G , Hashimoto C
    The requirement of CD80, CD86, and ICAM-1 on the ability of adjuvant formulations to potentiate antibody responses to a Plasmodium falciparum blood-stage vaccine.
    Vaccine. 2007;.
    PubMed     Text format     Related articles    Abstract available
    
    

Thank you for your interest in scientific medicine.

Amedeo is a Flying Publisher website.    Design: